(VIANEWS) – CEGEDIM (CGM.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| CEGEDIM (CGM.PA) | €19.26 | 2.56% | 5.08% |
| UCB (UCB.BR) | €85.12 | 1.61% | 4.81% |
| IBA (IBAB.BR) | €16.12 | 1.19% | 5.01% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. CEGEDIM (CGM.PA)
2.56% Forward Dividend Yield and 5.08% Return On Equity
Cegedim SA operates as a technology and services company in the digital data flow management for healthcare ecosystem and B2B, and business software publisher for healthcare and insurance professionals worldwide. It operates in two divisions, Health Insurance, HR and e-Services; and Healthcare Professionals. The Health Insurance, HR and e-Services division markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. This division also provides solutions for hosting, HR and payroll management outsourcing, and electronic data exchange services. The Healthcare Professionals division offers management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. The company was incorporated in 1969 and is headquartered in Boulogne-Billancourt, France. Cegedim SA is a subsidiary of FCB SA.
Earnings Per Share
As for profitability, CEGEDIM has a trailing twelve months EPS of €1.
PE Ratio
CEGEDIM has a trailing twelve months price to earnings ratio of 19.26. Meaning, the purchaser of the share is investing €19.26 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.08%.
Volume
Today’s last reported volume for CEGEDIM is 249 which is 93.11% below its average volume of 3615.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.2%, now sitting on 555.21M for the twelve trailing months.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 29, 2022, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 2.56%.
Volatility
CEGEDIM’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.29%, a positive 0.10%, and a positive 1.28%.
CEGEDIM’s highest amplitude of average volatility was 0.55% (last week), 1.16% (last month), and 1.28% (last quarter).
More news about CEGEDIM.
2. UCB (UCB.BR)
1.61% Forward Dividend Yield and 4.81% Return On Equity
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €2.14.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 39.78. Meaning, the purchaser of the share is investing €39.78 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.81%.
Volatility
UCB’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.62%, a negative 0.11%, and a positive 1.06%.
UCB’s highest amplitude of average volatility was 0.74% (last week), 0.92% (last month), and 1.06% (last quarter).
Sales Growth
UCB’s sales growth for the current quarter is negative 4.9%.
More news about UCB.
3. IBA (IBAB.BR)
1.19% Forward Dividend Yield and 5.01% Return On Equity
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for advance research in ConformalFLASH. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Earnings Per Share
As for profitability, IBA has a trailing twelve months EPS of €0.2.
PE Ratio
IBA has a trailing twelve months price to earnings ratio of 80.6. Meaning, the purchaser of the share is investing €80.6 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.01%.
Volume
Today’s last reported volume for IBA is 1848 which is 86.87% below its average volume of 14075.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, IBA’s stock is considered to be overbought (>=80).
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.5%, now sitting on 361.27M for the twelve trailing months.
Yearly Top and Bottom Value
IBA’s stock is valued at €16.12 at 12:30 EST, way below its 52-week high of €19.10 and way above its 52-week low of €11.76.
More news about IBA.
